Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Victorian Clinical Genetics Services, |
RCV004790006 | SCV005399183 | likely pathogenic | Ehlers-Danlos syndrome, type 4 | 2020-05-26 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as Likely Pathogenic. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene (PMID: 21637106). (N) 0104 - Dominant Negative is a mechanism of disease for this gene (PMID: 2934644). (N) 0108 - This gene is known to be associated with both recessive and dominant disease (OMIM). (N) 0112 – Missense variants in this gene have been reported with variable expressivity and variable age of onset (PMID: 28183226; GeneReviews). (N) 0200 - Variant is predicted to result in a missense amino acid change from glycine to arginine (exon 30). (N) 0251 - Variant is heterozygous. (N) 0301 - Variant is absent from gnomAD. (P) 0501 - Missense variant consistently predicted to be damaging by multiple in-silico tools or highly conserved with a major amino acid change. (P) 0601 - Variant affects at least one well-established (essential) functional domain or motif. This variant affects a glycine residue of the Gly-X-Y repeat within the triple helical region (PDB) (P) 0705 - No comparable variants have previous evidence for pathogenicity. (N) 0807 - Variant has not previously been reported in a clinical context. (N) 0905 - No segregation evidence has been identified for this variant. (N) 1007 - No published functional evidence has been identified for this variant. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign |